Citigroup initiated coverage on shares of Healthequity (NASDAQ:HQY) in a report released on Thursday, January 4th, The Fly reports. The firm issued a buy rating on the stock.
Several other equities analysts have also recently commented on the company. BidaskClub upgraded Healthequity from a sell rating to a hold rating in a research note on Friday, December 22nd. Cantor Fitzgerald reiterated a buy rating and set a $56.00 target price on shares of Healthequity in a research note on Tuesday, December 5th. Chardan Capital upped their price target on Healthequity from $58.00 to $62.00 and gave the company a buy rating in a research report on Wednesday, December 6th. Finally, Zacks Investment Research lowered Healthequity from a buy rating to a hold rating in a research report on Wednesday, November 15th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average target price of $58.33.
Shares of Healthequity (HQY) traded down $0.03 during mid-day trading on Thursday, reaching $48.92. 231,700 shares of the company traded hands, compared to its average volume of 443,311. Healthequity has a 12-month low of $37.62 and a 12-month high of $55.31. The firm has a market cap of $2,970.00, a P/E ratio of 66.11, a price-to-earnings-growth ratio of 2.02 and a beta of 1.74.
Healthequity (NASDAQ:HQY) last posted its quarterly earnings data on Tuesday, December 5th. The company reported $0.17 EPS for the quarter, beating the Zacks’ consensus estimate of $0.13 by $0.04. Healthequity had a net margin of 21.08% and a return on equity of 14.47%. The company had revenue of $56.80 million during the quarter, compared to the consensus estimate of $55.27 million. During the same quarter in the prior year, the company posted $0.10 EPS. The company’s quarterly revenue was up 31.0% compared to the same quarter last year. equities analysts expect that Healthequity will post 0.71 EPS for the current fiscal year.
In other news, Director Frank Medici sold 700 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $51.05, for a total transaction of $35,735.00. Following the completion of the sale, the director now directly owns 6,381 shares of the company’s stock, valued at approximately $325,750.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Darcy G. Mott sold 9,500 shares of the firm’s stock in a transaction dated Friday, October 20th. The stock was sold at an average price of $49.90, for a total value of $474,050.00. Following the sale, the vice president now directly owns 90,500 shares of the company’s stock, valued at $4,515,950. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,116,434 shares of company stock valued at $58,417,878. Company insiders own 19.00% of the company’s stock.
Several large investors have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in Healthequity by 4.3% in the 2nd quarter. BlackRock Inc. now owns 5,831,014 shares of the company’s stock valued at $290,559,000 after buying an additional 241,061 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Healthequity by 3.0% during the second quarter. Vanguard Group Inc. now owns 4,237,298 shares of the company’s stock worth $211,145,000 after acquiring an additional 122,061 shares during the last quarter. Wasatch Advisors Inc. raised its position in shares of Healthequity by 2.2% during the second quarter. Wasatch Advisors Inc. now owns 2,442,180 shares of the company’s stock worth $121,694,000 after acquiring an additional 52,885 shares during the last quarter. FMR LLC grew its stake in shares of Healthequity by 45.6% during the second quarter. FMR LLC now owns 2,235,150 shares of the company’s stock worth $111,378,000 after purchasing an additional 699,728 shares during the period. Finally, Janus Henderson Group PLC grew its stake in shares of Healthequity by 627.9% during the second quarter. Janus Henderson Group PLC now owns 2,113,030 shares of the company’s stock worth $105,292,000 after purchasing an additional 1,822,732 shares during the period. 98.25% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Healthequity (HQY) Receives New Coverage from Analysts at Citigroup” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/15/citigroup-begins-coverage-on-healthequity-hqy.html.
Healthequity Company Profile
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.